0.00Open0.05Pre Close0 Volume713 Open Interest6.00Strike Price0.00Turnover1902.73%IV10.81%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier-7DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1507Delta0.3453Gamma109.20Leverage Ratio-4.6012Theta0.0000Rho16.46Eff Leverage0.0001Vega
Vanda Pharmaceuticals Stock Discussion
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...
Vanda Pharmaceuticals Board of Directors Determines that Recent Unsolicited Takeover Proposals Are NOT in the Best Interests of the Company and its Shareholders
On June 19, 2024, Vanda Pharmaceuticals (Nasdaq: VNDA) announced its Board of Directors REJECTED unsolicited takeover proposals from Cycle Group Holdings and Future Pak The offers were $8.00 per share in cash from Cycle Group and $8.50-$9.00 per share in cash plus Contingent Value Rights (CVRs) from F...
Vanda Pharmaceuticals Confirms Receipt of Revised Unsolicited Takeover Proposal from Future Pak
Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 per Share
Benzinga· 1 min ago
Vanda Pharmaceuticals Announces Presentations at SLEEP 2024
Vanda Pharmaceuticals has announced its participation in SLEEP 2024, a conference set to take place in Houston, TX from June 1-5, 2024. The company will present four research studies on June 4, 2024, conducted by Dr. Sandra Paulina Smieszek, Head of Genetics. The presentations will cover drug and CRISPR/Cas9 screening of HCN channels, the impact of melanopsin crispants in zebrafish on sleep latency...
No comment yet